GLP-1 receptor agonist use may be associated with a modest increase in erectile dysfunction (ED) risk in men with type 2 ...

Adults with type 2 diabetes and overweight or obesity who use a GLP-1 receptor agonist have similar risk for kidney cancer as ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibitors were linked to lower risks for CKD and AKI but greater risks for albuminuria vs. GLP-1s. Risk ...

USA: Adults with type 2 diabetes who begin treatment with certain glucose-lowering medications may face differing risks for ...

As the number of people using these medications has soared, so have anecdotal reports about how they’re impacting users’ ...

GLP-1s are linked to a broad range of adverse events — largely gastrointestinal, metabolic, and psychological — across ...

SGLT2i initiation was associated with a 19% lower adjusted risk for CKD and a 12% lower rate of AKI events over 5 years compared to GLP-1RA initiation. Initiation of sodium-glucose co-transporter 2 ...

In a comparative study evaluating SGLT2 inhibitors and GLP-1 medications, the former drug class was associated with lower risk of chronic kidney disease and acute kidney injury. The study, published ...

A new study published in the journal of Bone that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was associated ...

Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present at the ...

The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in ...